使用去羟肌苷和替诺福韦进行维持性抗逆转录病毒治疗时病毒学失败率较高。

High rate of virological failure in maintenance antiretroviral therapy with didanosine and tenofovir.

作者信息

León Agathe, Mallolas Josep, Martinez Esteban, De Lazzari Elisa, Pumarola Tomás, Larrousse María, Milincovic Ana, Lonca Montserrat, Blanco Jose Luis, Laguno Montserrat, Biglia Alejandra, Gatell Josep María

机构信息

Infectious Diseases Unit, Hospital Clinic, University of Barcelona, Spain.

出版信息

AIDS. 2005 Oct 14;19(15):1695-7. doi: 10.1097/01.aids.0000186821.30489.16.

DOI:10.1097/01.aids.0000186821.30489.16

PMID:16184042

Abstract

We evaluated the virological outcome of tenofovir plus didanosine-based regimens in 67 HIV-suppressed patients. After a median follow-up of 26 months (IQR 10.5-40.5), 12 (18%) discontinued the therapy because of virological failure. At virological failure 'de novo' selected mutations were identified in 11 of the 12 failing patients, including the K65R mutation in seven patients. These results argue against the use of tenofovir-didanosine not only in naive patients, but also in previously suppressed patients.

摘要

我们评估了替诺福韦联合去羟肌苷方案在67例HIV得到抑制的患者中的病毒学转归。经过中位26个月的随访（四分位间距10.5 - 40.5），12例（18%）患者因病毒学失败而停止治疗。在病毒学失败时，12例失败患者中有11例检测到“新发”的特定突变，其中7例患者存在K65R突变。这些结果表明，不仅初治患者，而且既往病毒已得到抑制的患者都不适合使用替诺福韦-去羟肌苷方案。